Chemomab Therapeutics Ltd DRC (CMMB) — Strategic Asset Allocation Index
Chemomab Therapeutics Ltd DRC (CMMB) has a Strategic Asset Allocation Index of 1.6% as of December 2022. Strategic assets (PP&E of $594.00K plus long-term investments of $-) total $594.00K, measured against net assets of $36.22 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Chemomab Therapeutics Ltd DRC Strategic Asset Allocation Index (2018–2022)
This chart shows how Chemomab Therapeutics Ltd DRC's Strategic Asset Allocation Index has evolved across 5 annual periods from 2018 to 2022. As of December 2022, the index stands at 1.6%, representing strategic assets of $594.00K against net assets of $36.22 Million USD. Explore how efficiently does Chemomab Therapeutics Ltd DRC generate cash to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for Chemomab Therapeutics Ltd DRC (2018–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Chemomab Therapeutics Ltd DRC from 2018 to 2022, covering 5 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see Chemomab Therapeutics Ltd DRC (CMMB) market capitalisation.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 1.6% | $594.00K | $594.00K | $- | $36.22 Million | ▲ +0.5 pp |
| 2021 | 1.1% | $702.00K | $702.00K | $0.00 | $61.47 Million | ▼ -4.3 pp |
| 2020 | 5.4% | $584.00K | $580.00K | $4.00K | $10.80 Million | ▲ +3.2 pp |
| 2019 | 2.2% | $333.00K | $333.00K | $- | $14.91 Million | ▲ +0.7 pp |
| 2018 | 1.6% | $155.00K | $155.00K | $- | $9.80 Million | — |